Skip to main content
. Author manuscript; available in PMC: 2021 May 9.
Published in final edited form as: Cell Rep. 2021 Apr 13;35(2):108998. doi: 10.1016/j.celrep.2021.108998

Figure 5. Gasdermins segregate Val-boroPro pyroptosis from IL-1β release.

Figure 5.

Indicated genotypes of PMA-differentiated (100 ng/mL, 16 h) human THP-1 cells were treated with NLRP1 inflammasome activator Val-boroPro (2 μM).

(A) Immunoblots of these cells also were treated with nigericin (20 μM, 3 h) as pyroptosis positive control.

(B) Quantification of propidium iodide uptake and cell lysis through supernatant lactate dehydrogenase activity assay.

(C) Micrographs of Val-boroPro treatment. Arrows indicate classically pyroptotic cells that are swollen, speckled, transparent, and permeable to propidium iodide. Arrowheads indicate atypical, opaque cells that are impermeable to propidium iodide and opaque.

(D) Quantification of cell lysis induced with Val-boroPro with additional pretreatment with calpain and pan-caspase inhibitor z-VAD-fmk (20 μM, 0.5 h).

Scale bar, 50 μm. Immunoblots are representative of at least three independent experiments. Graph bars represent mean ± standard error of biological replicates. Graph points represent pooled technical replicates per biological replicate.